Ultomiris of long-term clinical benefit in myasthenia gravis patients
New Ultomiris (ravulizumab-cwvz) follow-up data shows sustained functional improvements in certain adults with generalised myasthenia gravis (gMG).
List view / Grid view
News
CFD airflow stimulations can help enhance cleanroom contamination control, finds study
Researchers used computational fluid dynamics (CFD) simulations to assess their cleanroom airflow and suggest improvements that would reduce contamination levels.
![Gilead sign at their headquarters in Silicon Valley, California USA[Credit: Michael Vi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Gilead-2-300x278.jpg)
![Gilead sign at their headquarters in Silicon Valley, California USA[Credit: Michael Vi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Gilead-2-e1642427117214.jpg)
Gilead opens paediatric drug development centre in Ireland
The new global paediatric drug development centre of excellence will focus on the creation of paediatric formulations to treat some of the world's most challenging viral diseases.
FDA approves first drug for PIK3CA-Related Overgrowth Spectrum (PROS) conditions
Novartis’ Vijoice® (alpelisib) is the first and only treatment approved for the treatment of the rare spectrum of conditions associated with PROS in certain patients.
Catalent acquires new biologics facility in the UK
Catalent announces the expansion of its biologics development and manufacturing capability by purchasing a new facility, currently under construction in Oxford, UK.
Designed for success – new SNA vaccine proves highly effective in mice
A team of scientists has developed a spherical nucleic acid (SNA) vaccine, which has demonstrated high efficacy as a COVID-19 therapy, as well as an anti-cancer treatment in rodents.
Big Pharma shares substance data to decrease animal testing
Four Big Pharma companies have shared previously unpublished hazard data for drug substances to enhance database-dependent computational tools and help reduce animal testing.
FUJIFILM acquires new cell therapy manufacturing facility
FUJIFILM Diosynth Biotechnologies will run the cell therapy manufacturing facility, acquired for $100mn from Atara Biotherapeutics, as part of its global network.
Sanofi launches pharma’s first Diversity, Equity & Inclusion Board
Sanofi’s new Diversity, Equity & Inclusion (DE&I) Board, and accompanying global Employee Resource Group (ERG) framework, will support the delivery of the company’s DE&I strategy.
Gene therapy shows promise in Wiskott–Aldrich syndrome
Lentiviral gene therapy reduces infections and bleeding episodes in children with a severe immune disorder Wiskott–Aldrich syndrome (WAS), finds new study.
Prototype AI test could predict promising cancer drug combinations
An artificial intelligence (AI)-based test was able to predict cancer patients’ response to drugs more accurately than is currently possible with genetic testing, finds proof-of-concept study.
UK cell and gene therapy manufacturing challenge ends in success
In a £1.3 million collaborative project Symbiosis and the Cell and Gene Therapy (CGT) Catapult reduced viral vector manufacturing times by more than 25 percent.
Positive top-line results for Etrasimod in treatment of ulcerative colitis
Phase III study results show ulcerative colitis patients treated with etrasimod achieved statistically significant improvements in clinical remission compared to placebo.
Implantable technology could enable in vivo CAR T therapy
Pre-clinical research demonstrates the potential of a new implantable biotechnology called MASTER to produce and release CAR T cells in vivo.
Teva recalls one lot of IDArubicin Hydrochloride Injection USP
Lot 31329657B of Teva’s IDArubicin Hydrochloride Injection USP 5mg/5ml vials is being recalled across the US due to particulates.
